With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
Hosted on MSN14d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz IntensifiesThis program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer. ImmunityBio said that Merck’s TICE BCG shortages have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback